ACE Inhibitors: Still a role for 40 year old drugs? episode artwork

EPISODE · Nov 19, 2024 · 18 MIN

ACE Inhibitors: Still a role for 40 year old drugs?

from For Kidneys Sake · host North West London Kidney Care

Do you have a question? Send it now...The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS)In this episode, Jeremy Levy and Andrew Frankel discuss the role of renin-angiotensin-aldosterone system inhibitors (RAASi) in the management of chronic kidney disease (CKD), looking deeper into the mechanisms, benefits and practical considerations of using RAASi. They cover when to initiate these medications, the importance of maximum dosing, monitoring kidney function, and managing side effects like changes in GFR and potassium levels.Key Takeaways:RAASi Benefits Beyond Blood Pressure:These drugs lower blood pressure, slow CKD progression, and provide cardiovascular protection through mechanisms independent of blood pressure control.Maximum dosing is essential for optimal kidney and heart protection.Monitoring and Managing GFR Changes:A GFR drop of up to 25% after starting RAASi is not a cause for concern.Clinicians should reassure patients and recheck levels to ensure stability.Potassium Management:Mild to moderate increases in potassium (up to 6 mmol/L) are common and generally not an emergency.Careful monitoring, addressing potential contributing factors, and avoiding unnecessary panic are key.This episode provides practical insights and actionable advice for clinicians managing CKD patients.Resource Links:NICE GUIDELINES [NG203] chronic kidney disease: assessment and management Overview | Chronic kidney disease: assessment and management | Guidance | NICENorthwest London CKD guidelines for primary care Chronic kidney disease (nwlondonicb.nhs.uk)The purpose of this podcast is to inform and educate health care professionals working in the primary care and community setting. The content is evidence based and consistent with NICE guidelines and North West Guidelines available at the time of publication.The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement.You can also join the community by signing up to our newsletter here Produced by award-winning media and marketing specialist Heather Pownall of Heather's Media Hub 

Episode metadata supplied by the publisher feed · Published Nov 19, 2024

Embed this episode

Do you have a question? Send it now... The For Kidneys Sake podcast series is brought to you by Imperial College Healthcare NHS Trust and North West London Integrated Care Board (NWL NHS) In this episode, Jeremy Levy and Andrew Frankel discuss the role of renin-angiotensin-aldosterone system inhibitors (RAASi) in the management of chronic kidney disease (CKD), looking deeper into the mechanisms, benefits and practical considerations of using RAASi. They cover when to initiate these me...

Distinct summary based on available episode metadata or transcript content.

Ready to play

ACE Inhibitors: Still a role for 40 year old drugs?

0:00 18:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of For Kidneys Sake?

This episode is 18 minutes long.

When was this For Kidneys Sake episode published?

This episode was published on November 19, 2024.

Is there a transcript available for this episode?

Yes, a full transcript is available for this episode. You can read the complete transcript on the episode page.

Can I download this For Kidneys Sake episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!